The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain and extra-terminal proteins, the readers of epigenetic acetylation marks, represents a novel therapeutic approach. Here, we have characterized the anti-tumour activity of the novel bromodomain and extra-terminal (BET) inhibitor BAY 1238097 in preclinical lymphoma models. BAY 1238097 showed anti-proliferative activity in a large panel of lymphoma-derived cell lines, with a median 50% inhibitory concentration between 70 and 208 nmol/l. The compound showed strong anti-tumour efficacy in vivo as a single agent in two diffuse large B cell lymphoma models. Gene expression profiling showed BAY 1238097 targeted the NFKB/ TLR/JAK/STAT signalling pathways, MYC and E2F1-regulated genes, cell cycle regulation and chromatin structure. The gene expression profiling signatures also highly overlapped with the signatures obtained with other BET Bromodomain inhibitors and partially overlapped with HDAC-inhibitors, mTOR inhibitors and demethylating agents. Notably, BAY 1238097 presented in vitro synergism with EZH2, mTOR and BTK inhibitors. In conclusion, the BET inhibitor BAY 1238097 presented promising anti-lymphoma preclinical activity in vitro and in vivo, mediated by the interference with biological processes driving the lymphoma cells. Our data also indicate the use of combination schemes targeting EZH2, mTOR and BTK alongside BET bromodomains.
The members of the bromodomain and extra-terminal (BET) (Emadali et al, 2013) family (BRD2, BRD3, BRD4 and BRDT) bind to acetylated proteins, including histones H3 and H4 (Filippakopoulos et al, 2012) , thereby acting as epigenetic readers, especially at the so-called super-enhancers, the clusters of enhancers incorporating high amounts of transcription factors and co-activators and regulating the expression of key genes controlling cell identity in normal cells and of oncogenes in cancer cells (Dawson et al, 2012; Hnisz et al, 2013) . Targeting BET proteins has recently emerged as a novel and promising therapeutic approach to interfere with cancer cell transcription programmes both in haematological and solid tumours (Dawson et al, 2011; Delmore et al, 2011; Mertz et al, 2011; Lockwood et al, 2012; Chapuy et al, 2013; Emadali et al, 2013; Picaud et al, 2013 ; (Lejeune et al, 2015) , entered early clinical evaluation (Postel-Vinay et al, 2016) .
Material and methods

Cell lines and molecules
Established human cell lines derived from 27 diffuse large B-cell lymphoma (DLCBL) [20 germinal centre B-cell (GCB)-DLBCL: FARAGE, OCI-LY-1, OCI-LY-2, OCI-LY-7, OCI-LY-8, OCI-LY-18, OCI-LY-19, RCK8, VAL, SU-DHL-4, SU-DHL-5, SU-DHL-6, SU-DHL-8, SU-DHL-10, SU-DHL-16, KARPAS422, WSU-DLCL2, DOHH2, Pfeiffer, TOLEDO; seven activated B-cell (ABC)-DLBCL: RI-1 (RIVA), HBL-1, TMD8, U2932, SU-DHL-2, OCI-LY-3, OCI-LY-10], 10 mantle cell lymphoma (MCL: GRANTA-519, JeKo-1, JVM-2, MAVER-1, MINO, REC-1, SP-49, SP-53, UPN-1 and Z-138), three splenic marginal zone lymphoma (SMZL: KARPAS1718, VL51, SSK41), nine anaplastic large T cell lymphoma (ALCL: JB6, Ki-JK, KARPAS-299, L-82, SUP-M2, SU-DHL-1, TS, FEPD, MAC-1), one pro-lymphocytic leukaemia (MEC-1) and one primary mediastinal large cell lymphoma (KARPAS1106P) were cultured in culture media as previously indicated (Boi et al, 2013) . The cell lines have been authenticated for cell identity and for Interspecies contamination (IDEXX BioResearch, Ludwigsburg, Germany). BAY 1238097 (patent application WO2014026997, example 127Á1) was provided by Bayer AG (Berlin, Germany) and dissolved in dimethyl sulphoxide (DMSO) to obtain a stock concentration of 10 mmol/l. Other compounds used were: ibrutinib, GSK126, everolimus (Selleckchem, Houston, TX, USA), and DZNep (Sigma Aldrich, St. Louis, MO, USA).
Cell proliferation, cell death, cell cycle analysis
The anti-proliferative activity of BAY 1238097 was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and the doses corresponding to the 50% inhibitory concentration (IC 50 ) and the 50% lethal concentration (LC 50 ) were estimated as previously described . Apoptosis and cell cycle distribution were evaluated on cells treated with DMSO or different doses of the compound, as previously reported (Boi et al, 2013) .
Western blotting analysis
Protein extraction, separation and immunoblotting were performed as previously described (Boi et al, 2013 
Chromatin immunoprecipitation (ChIP)
Data mining of the publicly available chromatin immunoprecipitation sequencing (ChIP-Seq) dataset SRP043524 (Ceribelli et al, 2014) and ChIP were performed as previously described (Boi et al, 2015) . Quantitative real-time polymerase chain reaction (PCR) of ChIP-DNA was performed using primers specific for a locus of BRD4 binding in the upstream regulatory region of EZH2 (chr7:148, 502, 583, 441) , as determined by analysing the ChIP-Seq dataset SRP043524 (Ceribelli et al, 2014) ; primers specific for human alphasatellite were used as a negative control (sequences available upon request).
Real-time polymerase chain reaction (PCR)
RNA was extracted using the RNeasy kit (Qiagen AG, Hombrechtikon, Switzerland). Real-time PCR was performed as previously described (Boi et al, 2013 ) (primer sequences available upon request).
Gene expression profiling
Gene expression profiling (GEP) was performed with the HumanHT-12 v4 Expression BeadChip (Illumina, San Diego, CA), as previously described (Boi et al, 2015) . For GEP comparison after exposure to the compound or DMSO, probes presenting a false discovery rate (FDR), controlled by the Benjamini-Hochberg algorithm, <0Á05 and a log ratio > |1| were considered differentially expressed using the empirical Bayes (paired) moderated t-test as implemented in the LIMMA R-package (Smyth, 2005) . Gene set enrichment was defined with gene set enrichment analysis (GSEA; Subramanian et al, 2005) on pre-ranked lists using the MSigDB 5.2 (Subramanian et al, 2005) and the SignatureDB collection (Shaffer et al, 2006) applying a threshold based on FDR < 0Á1.
For exploratory analyses performed on baseline gene expression profiles of cell lines with different degrees of sensitivity to compounds, probes presenting a P < 0Á05 and a log ratio > |1| were defined as differentially expressed using the empirical Bayes (paired) moderated t-test as implemented in CARMAweb 1.6 (Rainer et al, 2006) . Gene set enrichment was defined with GSEA (Subramanian et al, 2005) applying a threshold based on FDR < 0Á1.
GEP raw data are available at the National Center for Biotechnology Information Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) database under the accession number GSE93032 and GSE94669. 
In vivo experiments
Animal experiments were approved by the relevant regulatory agency of the federal state of Berlin (Landesamt f€ ur Gesundheit und Soziales, Berlin, Germany). Animals were housed according to institutional guidelines with access to food (pelleted diet) and water ad libitum. Severe combined immunodeficiency (SCID) female mice, 9-12 weeks old were inoculated subcutaneously into the right flank with 5 9 10 6 SU-DHL-8 cells/mouse suspended in 0Á1 ml of matrigel or with OCI-LY-3 tumour fragments (3 9 3 mm). BAY 1238097 was prepared as a solution in NaCl 0Á9% in water, pH 4 and administered orally at 10 ml/kg. Treatments with BAY 1238097 or vehicle control were initiated on day 4 posttumour inoculation for the SU-DHL-8 model (8 mice/ group). BAY 1238097 was applied daily for 12 days at its maximal tolerated dose (MTD) of 15 mg/kg. Treatment of the OCI-LY-3 tumours started on day 21 post-tumour inoculation, with mice being randomized with a median tumour size per group of 98 mm 3 for the BAY 1238097-treated group (n = 7) and 93 mm 3 for the vehicle control group (n = 8). BAY 1238097 was applied at the MTD of 45 mg/kg using an intermittent schedule, twice a week, for 4 weeks. Tumours were measured twice a week using a calliper and volume was calculated using the formula: tumour volume = [length 9 width 9 width]/2. Treated/control ratio (T/C) was calculated at the end of the study as follows: T/C = (median tumour volume in the treated group/median tumour volume in the vehicle control group) 9 100. A T/C ≤ 42% was declared active in agreement with NCI criteria (Voskoglou-Nomikos et al, 2003) . Differences in tumour volumes were calculated using the Wilcoxon ranksum test (STATA/SE 12.1 for Mac, STATA Corporation, College Station, TX). The P-value (P) for significance was <0Á05. Mice body weight was determined daily and body weight loss ≥20%, compared to the first day of therapy, was judged excessive and the dose considered as toxic.
Drug combinations and evaluation of synergism
Drug combination evaluation was performed as previously described (Boi et al, 2015) . Combinations were defined to be synergistic if the Chou-Talalay Combination Index (CI) was <0Á9, additive if the CI was between 0Á9 and 1Á1 and antagonistic/no benefit, if the CI was >1Á1 (Chou, 2010) .
Results
BAY 1238097 has in vitro anti-tumour activity in lymphoma models
We evaluated the anti-proliferative activity of the BET inhibitor BAY 1238097 in a panel of cell lines derived from ABC DLBCL (n = 7), GCB DLBCL (n = 20), MCL (n = 10); SMZL (n = 3), primary mediastinal large cell lymphoma (PMBCL, n = 1), chronic lymphocytic leukaemia (CLL, n = 1) and ALCL (n = 9). As assessed by MTT assays performed after 72 h of drug exposure, BAY 1238097 was active in a dose-dependent manner in almost all the cell lines ( Fig 1A) with a median IC 50 value of 231 nmol/l (95% CI, 161-280 nmol/l). The compound had higher activity in B cell than in T cell models (P < 0Á001), while no differences were observed among B-cell tumour types (DLBCL, MCL, SMZL) or DLBCL subtypes (ABC, GCB).
We compared the activity of BAY 1238097 with our previous results obtained using the BET inhibitor OTX015 (MK-8628) on B cell-derived lymphomas (Boi et al, 2015) . When focusing (R 2 = 0Á42, P = 0Á0197), BAY 1238097 presented a similar pattern of activity with OTX015. The anti-tumour activity of BAY 1238097 was mainly cytostatic as indicated by the distribution of LC 50 values, which were higher than 1 lmol/l in 84% (43/51) of the cells exposed to BAY 1238097. Fig 1B and Figure S1A shows the validation in the eight cell lines with a LC 50 <1 lmol/l, and in one with higher LC 50 value (U2932). Time-dependent apoptosis was observed in the eight cell lines treated for 72 or 96 h with a dose of 500 nmol/l. The cytostatic activity was shown by treating six DLBCL cell lines (Farage, DOHH-2, Toledo, KARPAS-422, SU-DHL-4 and WSU-DLCL2) with BAY 1238097 (500 nmol/l, 72 h), which induced cell cycle arrest in G1 with decreased G2/M phase (Fig 1C and Figure S1B) .
BAY 1238097 has in vivo anti-tumour activity in lymphoma models
We assessed the in vivo ability of BAY 1238097 to reduce tumour growth in two DLBCL models implanted in SCID female mice. The first model was obtained by engraftment of a GCB-DLBCL cell line (SU-DHL-8) (Fig 2A, Figure S2A ). BAY 1238097, given at the MTD of 15 mg/kg p.o. using a daily schedule), significantly affected tumour growth in comparison with the control group, with a T/C of 15% on day 14 post-tumour inoculation (P < 0Á001). The second model was obtained by engraftment of an ABC-DLBCL cell line (OCI-LY-3) (Fig 2B, Figure S2B ). Treatment with BAY 1238097 at the MTD of 45 mg/kg (p.o. with a twice weekly schedule) also significantly inhibited tumour growth, with a T/C of 23% on day 48 post-tumour inoculation (P < 0Á001). BAY 1238097 treatments were overall well tolerated with a maximal mean body weight loss of 6% on day 9 in the SU-DHL-8 study and 9% on day 45 in the OCI-LY-3 model.
BAY 1238097 affects the gene expression of GCB DLBCL cells
To understand the mechanism of action of BAY 1238097 in DLBCL, we performed a GEP study on the cell line DOHH-2 exposed to DMSO or BAY 1238097 (500 nmol/l) for 8, 12 or 24 h (Fig 3A-B and Table SI ). We first looked at the genome-wide changes induced by the compound. BAY 1238097 decreased target genes of MYC, NOTCH and E2F, members of the NFKB/MYD88 and mTOR/AKT signalling pathways. The upregulated transcripts were mainly represented by histones. The GEP signatures highly overlapped with the signatures obtained with other BET inhibitors and partially overlapped with HDAC or mTOR inhibitors and demethylating agents. At the gene level, 143 probes (121 annotated transcripts) were downregulated and 71 (59 annotated transcripts) were upregulated. BTK, CCDC86, CCND2, CD19, CD27, FAIM, FCMR (FAIM3), IL7R, IRAK1, MAPK13, MYB, MYC, PDE4B, TNFRSF13B, TNFRSF17 were among the top downregulated genes. Beside histone-coding genes, the upregulated genes included CCL5, CDKN2C, CD69, JUN, and MKNK2.
BAY 1238097 downregulates EZH2 expression and synergizes with EZH2 inhibitors
Analysis of genomic alterations in the cell lines exposed to BAY 1238097 revealed that the presence of somatic mutations in the EZH2 gene was associated with higher sensitivity to the BET inhibitor (P = 0Á007), which was maintained when considering only the cell lines derived from GCB-DLBCL (P = 0Á025) (Fig 4A) , in which mutations more frequently occur Dalla Favera, 2017 ). An EZH2 signature obtained comparing series of follicular lymphomas with mutated EZH2 versus wild type cases (Guo et al, 2014) appeared enriched in the transcripts high in GCB-DLBCL with higher sensitivity to BAY 1238097 (NES = 1Á6, P < 0Á01) (Fig 4B) . Due to this association between EZH2 mutations and BAY 1238097 activity (500 nmol/l for 3 h). Cells were fixed with formaldehyde and subjected to the ChIP assay. Anti-IgG served as a negative control for the ChIP assay. Quantitative real-time polymerase chain reaction showed the enrichment of BRD4 binding in the upstream regulatory regions of EZH2, which decreased following treatment with BAY 1238097. Amplification of the centromeric human alpha satellite sequence served as a negative control. For each primer set, results were normalized to total input chromatin DNA samples. DMSO, dimeythyl sulphoxide; MUT, mutated; NES, normalized enrichment score; WT, wild type. [Colour figure can be viewed at wileyonlinelibrary.com] we evaluated whether EZH2 was regulated in a BET bromodomain-dependent manner. We took advantage of publicly available ChIP-Seq data for the HBL1 DLBCL model treated with the BET inhibitor JQ1 (Ceribelli et al, 2014) . The EZH2 upstream regulatory region presented binding of BRD4, and JQ1 treatment (500 nmol/l, 3 h) reduced the BET Bromodomain binding, indicating a direct effect of BET Bromodomain on the regulation of EZH2 expression (Fig 4C-D) .
Based on these findings we assessed the possible therapeutic benefit of the dual inhibition of both BET Bromodomain and EZH2. To pursue this aim, we first exposed eight GCB-DLBCL cell lines (five mutated EZH2, three wild-type EZH2 protein) to BAY 1238097 and to the EZH2-inhibitor DZNep for 72 h (Miranda et al, 2009) . Benefit was observed in three cell lines, all with mutated EZH2 (synergism in WSU-DLCL2 and KARPAS-422, additive effect in the SU-DHL-6) ( Fig 5A) . Similar results were obtained combining BAY 1238097 with a second, more selective, EZH2 inhibitor, GSK126, used at concentrations in accord with a previous work (McCabe et al, 2012) : the same three EZH2 mutated cell lines achieved a benefit from the combination treatment (Fig 5B) .
Based on these data we assessed changes at protein levels of EZH2, total histone H3 and H3K27me3 after exposure to BAY 1238097 as a single agent and in combination with GSK126. BET inhibitor treatment was followed by a downregulation of EZH2, histone H3 and H3K27me3 levels. A stronger downregulation of H3K27me3 levels after treatment with the BAY 1238097/GSK126 combination was observed (Fig 5C) . Similar results were obtained using DZNep (data not shown).
Baseline features are associated with response to BAY 1238097
The anti-proliferative activity of BAY 1238097 was not associated with MYC/BCL2/BCL6 single/double translocations, KMT2D (MLL2), MYD88, FOXO1 mutations, or TP53 status. To identify genes and pathways that might predict sensitivity to the novel BET inhibitor, we compared the baseline gene expression profiles of cell lines with a BAY 1238097 IC 50 lower than 500 nmol/l versus those with a higher IC 50 . The analysis was limited to GCB DLBCL due to sample size. Transcripts with higher expression in the most sensitive GCB DLBCL cells (n = 10) were enriched with genes involved in JAK/STAT, IFN and BCR signalling, while the less sensitive GCB DLBCL (n = 4) had higher expression of genes involved in cell cycle, chromatin structure and E2F1 targets ( Figure S3 and Table SII) .
BAY 1238097 shows in vitro synergism with the mTOR inhibitor everolimus
Based on the above-mentioned similarity between gene expression changes following exposure to BAY 1238097 and mTOR-inhibitors, BAY 1238097 was combined with the mTOR inhibitor everolimus, leading to a therapeutic benefit in 7/8 DLBCL cell lines: synergism in 2/2 ABC-DLBCL (U-2932, TMD8) and in 5/6 GCB-DLBCL (KARPAS-422, SU-DHL-6, DOHH-2, SU-DHL-8, Toledo) (Fig 6A) . Treatment of two DLBCL cell lines with only BAY 1238097 induced a downregulation of pAKT (Fig 6B) , which was maintained in the cell lines exposed to both compounds.
BAY 1238097 shows in vitro synergism with the BTK inhibitor ibrutinib
As mentioned above, a high expression of JAK/STAT and IFN signalling genes was positively associated with sensitivity to BAY 1238097, which also downregulated the NFKB/ MYD88 pathway, including the BTK transcript. Among all cell lines exposed to the compound, the presence of the MYD88 L265P somatic mutation was associated with higher sensitivity to the BET inhibitor in ABC DLBCL cell lines (P = 0Á05). We assessed the combination of BAY 1238097 with the BTK-inhibitor ibrutinib and observed synergism in 2/2 ABC-DLBCL cell lines harbouring the MYD88 L265P mutation (OCI-LY-10, TMD8). No benefit was observed in the two ABC-DLBCL cell lines bearing wild-type MYD88 (SU-DHL-2, U-2932) ( Figure S4 ).
Discussion
We have evaluated the activity of the BET Bromodomain inhibitor BAY 1238097 in pre-clinical models of mature lymphoid tumours, and found that: (i) BAY 1238097 had a wide anti-proliferative activity, which was mostly cytostatic; (ii) BAY 1238097 affected cellular pathways relevant for the lymphoma cells; (iii) sensitivity to BAY 1238097 was associated with phenotypic and genetic features; (iv) BAY 1238097 reduced EZH2 expression and synergized with EZH2 inhibitors; (v) BAY 1238097 synergized with mTOR and BTK inhibitors.
The anti-tumour activity of BAY 1238097 was higher in cell lines derived from B cell lymphoma compared to those derived from T cell lymphoma but it did not differ further based on lymphoma histotype or the presence of genetic lesions such as MYC gene translocation or TP53 inactivation. The three compounds shared a very similar pattern of activity across all the tested lymphoma models, which also partially correlated with what was previously observed with other BET inhibitors such as OTX015 and JQ1 (Chapuy et al, 2013; Boi et al, 2015) . The anti-tumour activity of BAY 1238097 was furthermore confirmed in two in vivo DLBCL xenograft models where a strong efficacy was demonstrated when the compound was administered orally using either a daily or a twice-weekly schedule. As for other targeted agents (Ezell et al, 2014; Boi et al, 2015) , the activity was mostly cytostatic, with very few cell lines derived from ABC DLBCL [as seen with OTX015 (Boi et al, 2015) ], from GCB DLBCL and from MCL, undergoing apoptosis after 72 h of drug exposure. Clinical trials will indicate whether these types of anti-tumour drugs, as single agents, require continuous or prolonged schedules due to their mostly cytostatic activity.
Baseline GEP is a strategy to identify mutations and features associated with response to a compound and to suggest possible combinatorial schemes. The cells with the highest sensitivity to BAY 1238097 had not only high expression levels of genes involved in JAK/STAT, IFN and BCR signalling, but also higher incidence of somatic mutations in EZH2 and MYD88, which could represent potential biomarkers. These data also suggested rational combinations to be further explored. Gain-of-function mutations of EZH2 gene frequently occur in GCB DLBCL and follicular lymphomas Dalla Favera, 2017) . Here, both the mutation and an EZH2 gene expression signature derived from follicular lymphomas were associated with higher sensitivity to BAY 1238097 in GCB-DLBCL. This prompted us to look at the effect of BAY 1238097 on EZH2 expression and to possible therapeutic consequences. The analysis of publicly available ChIP-Seq data (Ceribelli et al, 2014) indicated that EZH2 is indeed expressed in a BRD4-depenedent manner in DLBCL, and in accordance with the data reported by Wu et al (2016) , JQ1 can inhibit the binding. When we treated DLBCL cells with BAY 1238097 we observed a downregulation of EZH2 and, more importantly, of H3K27me3, the marker of EZH2 activity. Interestingly, this led to a synergism when we combined pharmacological inhibition of both BET Bromodomains and EZH2, suggesting that this combination of epigenetic drugs is worth further preclinical and clinical investigations.
Besides regulating EZH2 levels, BAY 1238097 decreased MYC, target genes of MYC, Notch and E2F, as well as members of the NFKB/MYD88 and mTOR/AKT signalling pathways, changes that are in line with what was seen previously with other BET inhibitors (Chapuy et al, 2013; Picaud et al, 2013) .
Finally, based on these expression changes and on data previously reported by us and others (Ceribelli et al, 2014; Boi et al, 2015; Lee et al, 2015; Sun et al, 2015; Gaudio et al, 2016; Vazquez et al, 2017) , we evaluated the combination of BAY 1238097 with the BTK inhibitor ibrutinib and the mTOR inhibitor everolimus. Synergism was observed when combining BAY 1238097 and the BTK inhibitor in the ibrutinib-sensitive ABC-DLBCL cell lines while no benefit was observed in ibrutinib-resistant ABC-DLBCL cells, suggesting that the addition of the BET inhibitor cannot overcome a genetically driven resistance. In accordance to what was seen with the BET inhibitor OTX015 (Boi et al, 2015) , the combination of BAY 1238097 with everolimus was highly beneficial in both ABC DLBCL and GCB DLBCL cells. Immunoblotting data suggested that the synergism could be due to decreased levels of pAKT after BET inhibitor treatment, which might attenuate the negative feedback observed after applying mTOR inhibitors alone (Gupta et al, 2009 ).
In conclusion, the BET inhibitor BAY 1238097 showed a clear anti-lymphoma preclinical activity mediated by interfering with biological processes driving the lymphoma cells. Our data also indicate the use of combination schemes targeting EZH2, mTOR and BTK alongside BET Bromodomains. 
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Supporting Information
Additional Supporting Information may be found in the online version of this article: Fig S1 . The anti-tumor activity of BAY 1238097 is mainly cytostatic. (A) Apoptosis was evaluated by Annexin-V/7-AAD staining in cell lines exposed to 500 nmol/l of BAY 1238097 for 96 h or to DMSO control. (B) Cell cycle analysis of cells treated with BAY 1238097 (500 nmol/l for 72 h) or DMSO. Fig S2. Distribution of tumor volumes in two diffuse large B-cell lymphoma xenografts models treated with BAY 1238097 or with vehicle. In each box-plot, the line in the middle of the box represents the median and the box extends from the 25th to the 75th percentile (interquartile range, IQ); the whiskers extend to the upper and lower adjacent values (i.e., AE1.5 IQ). (A) SCID mice subcutaneously inoculated with the GCB DLBCL SU-DHL-8 cell line and treated with BAY 1238097 (n = 8) or vehicle control (n = 8): tumor volumes differences between treated and control mice were statistically significant starting on day 10. (B). SCID mice subcutaneously inoculated with the ABC DLBCL OCILY-3 cell line and treated with BAY 1238097 (n = 7) or vehicle control (n = 8): tumor volumes differences between treated and control mice were statistically significant starting on day 27. Fig S3. Gene expression profiling features are associated with response to BAY 1238097. Representative GSEA plots illustrating the gene-set enrichment in transcripts with higher expression in the most sensitive GCB DLBCL cells (IC50 < 500 nmol/l) when compared to the less sensitive GCB DLBCL cells (IC50 > 500 nmol/l). Fig S4. BAY 1238097 shows in vitro synergism with the BTK inhibitor ibrutinib. Combination of BAY 1238097 with the BTK inhibitor ibrutinib in four ABC-DLBCL cell lines. Y-axis: combination index (CI) values (<0.3, strong synergism; 0.3-0.9, synergism; 0.9-1.1, additive effect; >1.1, no benefit/antagonism). In each box-plot, the line in the middle of the box represents the median and the box extends from the 25th to the 75th percentile (interquartile range, IQ); the whiskers extend to the upper and lower adjacent values (i.e., 1.5 IQ) and outside values have been omitted from the figure. Table SI . Gene expression changes in one GCB DLBCL cell line after exposure to DMSO or BAY 1238097 (500 nmol/l) for 8, 12 or 24 h. GSEA of transcripts downregulated (A) or upregulated (B) in the GCB DLBCL cell line DOOH2 after exposure to BAY 1238097 compared to DMSO treated cells. In, A and B: FDR, false discovery rate; NES, normalized enrichment score. (C) Transcripts differentially expressed between GCB DLBCL cell line DOHH2 after exposure to BAY 1238097 compared to DMSO treated cells. Table SII . Baseline gene expression analysis of GCB DLBCL cell lines with higher (IC50 < 500 nM) or lower sensitivity (IC50 > 500 nM) to BAY 1238087. GSEA of transcripts downregulated (A) or upregulated (B) in ten GCB DLBCL cell lines with high sensitivity to BAY 1238097 when compared with four less sensitive GCB DLBCL cell lines. In, A and B: FDR, false discovery rate; NES, normalized enrichment score. (C) Transcripts differentially expressed between GCB DLBCL cell lines with higher or lower sensitivity to BAY 1238097.
